Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F/TAF Switch Study in HIV-1 Virologically Suppressed Children
NCT02285114Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2015
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Jan 2015; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02285114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285114.